122 related articles for article (PubMed ID: 8971799)
21. Characterization of [125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle.
Burris KD; Filtz TM; Chumpradit S; Kung MP; Foulon C; Hensler JG; Kung HF; Molinoff PB
J Pharmacol Exp Ther; 1994 Feb; 268(2):935-42. PubMed ID: 8114008
[TBL] [Abstract][Full Text] [Related]
22. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
Elsner J; Boeckler F; Heinemann FW; Hübner H; Gmeiner P
J Med Chem; 2005 Sep; 48(18):5771-9. PubMed ID: 16134944
[TBL] [Abstract][Full Text] [Related]
23. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
24. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography.
Landwehrmeyer B; Mengod G; Palacios JM
Eur J Neurosci; 1993 Feb; 5(2):145-53. PubMed ID: 8261096
[TBL] [Abstract][Full Text] [Related]
25. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer.
McCormick PN; Fletcher PJ; Wilson VS; Browne JD; Nobrega JN; Remington GJ
Neuropharmacology; 2015 Feb; 89():225-31. PubMed ID: 25283483
[TBL] [Abstract][Full Text] [Related]
26. Identification of D3 and sigma receptors in the rat striatum and nucleus accumbens using (+/-)-7-hydroxy-N,N-di-n-[3H]propyl-2-aminotetralin and carbetapentane.
Wallace DR; Booze RM
J Neurochem; 1995 Feb; 64(2):700-10. PubMed ID: 7830063
[TBL] [Abstract][Full Text] [Related]
27. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297.
Flores-Tochihuitl J; Vargas G; Morales-Medina JC; Rivera G; De La Cruz F; Zamudio S; Flores G
Synapse; 2008 Jan; 62(1):40-9. PubMed ID: 17957737
[TBL] [Abstract][Full Text] [Related]
28. Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain.
Flietstra RJ; Levant B
Life Sci; 1998; 62(20):1825-31. PubMed ID: 9600324
[TBL] [Abstract][Full Text] [Related]
29. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors.
Seeman P
Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435
[TBL] [Abstract][Full Text] [Related]
30. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Ryoo HL; Pierrotti D; Joyce JN
Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
[TBL] [Abstract][Full Text] [Related]
31. Ontogeny of dopamine D3 receptors in the nucleus accumbens of the rat.
Stanwood GD; McElligot S; Lu L; McGonigle P
Neurosci Lett; 1997 Feb; 223(1):13-6. PubMed ID: 9058411
[TBL] [Abstract][Full Text] [Related]
32. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
33. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
34. Developmental regulation of expression of the D3 dopamine receptor in rat nucleus accumbens and islands of Calleja.
Gurevich EV; Himes JW; Joyce JN
J Pharmacol Exp Ther; 1999 Apr; 289(1):587-98. PubMed ID: 10087054
[TBL] [Abstract][Full Text] [Related]
35. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
[TBL] [Abstract][Full Text] [Related]
36. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats.
Le Foll B; Diaz J; Sokoloff P
Synapse; 2003 Mar; 47(3):176-83. PubMed ID: 12494400
[TBL] [Abstract][Full Text] [Related]
37. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.
Gerlach M; Double K; Arzberger T; Leblhuber F; Tatschner T; Riederer P
J Neural Transm (Vienna); 2003 Oct; 110(10):1119-27. PubMed ID: 14523624
[TBL] [Abstract][Full Text] [Related]
38. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.
Kreiss DS; Bergstrom DA; Gonzalez AM; Huang KX; Sibley DR; Walters JR
Eur J Pharmacol; 1995 Apr; 277(2-3):209-14. PubMed ID: 7493610
[TBL] [Abstract][Full Text] [Related]
39. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study.
Cagnotto A; Parotti L; Mennini T
Eur J Pharmacol; 1996 Oct; 313(1-2):63-7. PubMed ID: 8905329
[TBL] [Abstract][Full Text] [Related]
40. Quantitative autoradiography of Gpp(NH)p sensitive and insensitive [3H]quinpirole binding sites in the rat brain.
Gehlert DR
Synapse; 1993 Jun; 14(2):113-20. PubMed ID: 8101393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
